Abstract |
The prognostic effect of hypogammaglobulinemia (HGG), clinical and biologic characteristics on the infection risk and outcome has been retrospectively analyzed in 899 patients with stage A chronic lymphocytic leukemia (CLL). Low levels of IgG were recorded in 19.9% of patients at presentation, low levels of IgM and/or IgA in 10.4% and an additional 20% of patients developed HGG during the course of the disease. Before the start of any treatment, 160 (12.9%) patients experienced at least one grade ≥3 infection requiring a systemic anti-infective treatment and/or hospitalization. While IgG levels at diagnosis were not associated with an increased risk of grade ≥3 infection or with an adverse outcome, a significantly increased rate of grade ≥3 infections was recorded in patients with unmutated IGHV (p=0.011) and unfavorable FISH aberrations (p=0.009). Late onset HGG, more frequently recorded in patients with Rai stage I-II (p=0.001) and unmutated IGHV (p=0.001), was also associated with a higher rate of severe infections (p=0.002). These data indicate that, stage A patients with clinical and biologic characteristics of a more aggressive disease develop more frequently late onset HGG, grade ≥3 infections and require a closer clinical monitoring.
|
Authors | Francesca R Mauro, Fortunato Morabito, Iolanda D Vincelli, Luigi Petrucci, Melissa Campanelli, Adriano Salaroli, Giuseppina Uccello, Annamaria Petrungaro, Francesca Ronco, Sara Raponi, Mauro Nanni, Antonino Neri, Manlio Ferrarini, Anna R Guarini, Robin Foà, Massimo Gentile |
Journal | Leukemia research
(Leuk Res)
Vol. 57
Pg. 65-71
(06 2017)
ISSN: 1873-5835 [Electronic] England |
PMID | 28292720
(Publication Type: Journal Article)
|
Copyright | Copyright © 2017 Elsevier Ltd. All rights reserved. |
Chemical References |
- Immunoglobulin G
- Single-Domain Antibodies
|
Topics |
- Adult
- Agammaglobulinemia
(complications, diagnosis)
- Aged
- Aged, 80 and over
- Humans
- Immunoglobulin G
(blood)
- Infections
(etiology)
- Leukemia, Lymphocytic, Chronic, B-Cell
(complications, pathology)
- Middle Aged
- Prognosis
- Retrospective Studies
- Risk
- Single-Domain Antibodies
(blood)
- Treatment Outcome
|